Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Collyar: What's In It for Patients?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Apr

Today In Oncology

Insights From the 2023 International Society of Geriatric Oncology Conference

Illuminating a Potential Culprit in Melanoma Treatment Resistance

Oxaliplatin-Based Adjuvant Therapy in Older Patients with Stage III Colon Cancer

Newly Diagnosed Locally Advanced HNSCC Adding Pembrolizumab to Concurrent Chemoradiotherapy

Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos